WAVEMAN · COMPANY

GSK · Gsk Plc

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

GSK

Name: GSK plc (GSK) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

GSK plc

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001131399

CONGRESS · 1FORM 144 · 1☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

493

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

1 member bought in the last year

the lowest in Pharma & Biotech

FUNDS

493 funds added or opened last quarter

more than 97% of Pharma & Biotech

REVENUE

no revenue reported in any filing

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

0.3% of shares outstanding short · 2.6 days to cover · settled 2026-07-31

below 81% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

493 funds added or opened positions in the latest 13F quarter, of 1,046 holders.

1 member of Congress reported buying it this year.

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows 493 funds added last quarter, 1 Congress member(s) bought in 12 months, $2.3M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for GSK plc in the period covered. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

no insider purchases or sales on record

0 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see the full history, the screener and CSV export, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

FMR LLC

64,961,641.0 sh

$3.4B

Dodge & Cox

48,197,514.0 sh

$2.5B

Fisher Asset Management, LLC

35,722,792.0 sh

$1.9B

PRIMECAP MANAGEMENT CO/CA/

25,182,068.0 sh

$1.3B

WELLINGTON MANAGEMENT GROUP LLP

11,396,249.0 sh

$597.4M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

Martinez Maria E

FILED 2026-08-20

$2.3M

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Select Pharmaceuticals Portfolio

$152.6M POSITION · AS OF 2026-02-28

10.1%

Callodine Equity Income Series

$11.9M POSITION · AS OF 2026-03-31

5.5%

VanEck Pharmaceutical ETF

$58.9M POSITION · AS OF 2026-03-31

4.6%

Sound Equity Dividend Income ETF

$1.4M POSITION · AS OF 2026-02-28

4.6%

ICON EQUITY INCOME FUND

$1.8M POSITION · AS OF 2026-03-31

4.2%

Huber Mid Cap Value Fund

$486.5K POSITION · AS OF 2026-04-30

3.9%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
GROSS PROFIT	$23.6B	$22.3B	$21.8B	$19.8B
NET INCOME	$6.3B	$3.0B	$5.3B	$15.6B

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE